Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
211At-BC8-B10 Followed by Haplo-Identical Allogeneic HCT for High-Risk Acute Leukemia or MDS
NCT03670966Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jul 2019
- Primary completion
- Jan 2028
- Modality
- Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [211At]BC8-B10 in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and 2 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Dose Limiting Toxicity at 60 days. Started Jul 2019; status: recruiting.
02
Drugs
[211At]BC8-B10
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT03670966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03670966.